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Abstract
The accelerated risk of cardiovascular disease (CVD) in Rheumatoid Arthritis (RA) requires further study of the underly-
ing pathophysiology and determination of the at-risk RA phenotype. Our objectives were to describe the cardiac structure 
and function and arterial stiffness, and association with disease phenotype in patients with established) RA, in comparison 
to healthy controls, as measured by cardiovascular magnetic resonance imaging (CMR). 76 patients with established RA 
and no history of CVD/diabetes mellitus were assessed for RA and cardiovascular profile and underwent a non-contrast 
3T-CMR, and compared to 26 healthy controls. A univariable analysis and multivariable linear regression model determined 
associations between baseline variables and CMR-measures. Ten-year cardiovascular risk scores were increased in RA 
compared with controls. Adjusting for age, sex and traditional cardiovascular risk factors, patients with RA had reduced left 
ventricular ejection fraction (mean difference − 2.86% (− 5.17, − 0.55) p = 0.016), reduced absolute values of mid systolic 
strain rate (p < 0.001) and lower late/active diastolic strain rate (p < 0.001) compared to controls. There was evidence of 
reduced LV mass index (LVMI) (− 4.56 g/m2 (− 8.92, − 0.20), p = 0.041). CMR-measures predominantly associated with 
traditional cardiovascular risk factors; male sex and systolic blood pressure independently with increasing LVMI. Patients 
with established RA and no history of CVD have evidence of reduced LV systolic function and LVMI after adjustment for 
traditional cardiovascular risk factors; the latter suggesting cardiac pathology other than atherosclerosis in RA. Traditional 
cardiovascular risk factors, rather than RA disease phenotype, appear to be key determinants of subclinical CVD in RA 
potentially warranting more effective cardiovascular risk reduction programs.
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Introduction
Rheumatoid arthritis (RA) is associated with an acceler-
ated risk of cardiovascular disease (CVD), with both tradi-
tional cardiovascular risk factors and systemic inflamma-
tion playing a role [1]. To improve on the European league 
against rheumatism (EULAR) recommendations for reduc-
ing CVD in RA [2], there is a need for greater understand-
ing of the underlying pathophysiology and determination 
of the RA phenotype most at risk of CVD.
Cardiovascular magnetic resonance (CMR) imaging 
provides highly reproducible quantitative assessment of 
the heart and cardiovascular system, with high diagnostic 
accuracy for ischaemic heart disease (IHD) [3]. CMR is 
increasingly used as a research tool in patients with RA, 
detecting the presence of subclinical disease in popula-
tions free of clinical CVD [4–8]. The largest CMR study 
in RA (n = 75, some with diabetes) reported a 4.4% reduc-
tion in LV ejection fraction (LVEF), but interestingly also 
a 15% reduction in LV mass index (LVMI) in those with 
RA [9]. A preliminary CMR report of 66 patients with 
treatment-naive early RA also demonstrated a reduced 
LVMI [10]. Both of these CMR studies stand in contrast 
to echocardiographic data [11] and smaller CMR studies in 
RA [8, 12] reporting no difference or increase in LV mass. 
This is of pathophysiological interest given the occurrence 
of heart failure in RA is not fully attributable to traditional 
cardiovascular risk factors or the presence of IHD [13].
This exploratory study describes cardiac structure and 
function and arterial stiffness in patients with established 
RA free of known CVD and diabetes mellitus, in compari-
son to healthy controls, as measured by CMR. The study 
also describes the association of any cardiovascular abnor-
malities with RA disease phenotype, to provide insight 
into the patients most at risk of CVD.
Methods
Consecutive patients with RA attending rheumatology 
clinics between January 2011 and September 2014 at the 
Leeds Teaching Hospitals NHS Trust were considered 
for this study. Patients were eligible if between 18 and 
80 years old, met 1987 ACR criteria [14], had disease for 
5 years or more and no history of CVD or diabetes mel-
litus. Healthy controls, with no history of RA or osteoar-
thritis affecting their mobility, were mainly identified by 
asking patients with RA to ‘bring a friend’. This study 
had full ethical approval; REC 09/H1307/98 and REC 10/
H1307/103, NRES Leeds West ethics committee. Follow-
ing written informed consent obtained according to the 
Declaration of Helsinki, study participants were invited 
to undergo a cardiovascular clinical assessment, fasting 
blood collection and CMR.
Clinical assessment
A clinical evaluation recorded demographic data, tradi-
tional cardiovascular risk factors and for patients with RA, 
disease phenotype including 3-variable DAS28-C-reactive 
protein (CRP) [15]) and Health Assessment Questionnaire-
Disease Index [16]. Fasting lipid profile and glucose were 
measured, and rheumatoid factor (RF), anti-cyclic citrul-
linated peptide antibody (ACPA), CRP, erythrocyte sedi-
mentation rate in those with RA. Additional blood samples 
were processed and stored (some at − 30 °C and some at 
− 80 °C) for later analysis at the Department of Biochemical 
Diagnostics, Medical University of Lublin, Poland; glucose 
(using biochemical analyser Cobas INTEGRA 400); N-ter-
minal pro-brain natriuretic peptide (NT-proBNP) (using 
Cobas 6000 (immunochemistry module Cobas e601)) and 
insulin (using COBAS e 411 (Roche Diagnostics GmbH, 
Mannheim, Germany) and appropriate Roche Diagnostics 
assays). Homeostasis model assessment-estimated insulin 
resistance (HOMA-IR) was then calculated (fasting insulin 
(μU/ml) × fasting glucose (mg/dl)/405) [17].
CMR imaging
The CMR study was performed on a 3T Philips Achieva 
system TX equipped with a 32-channel coil. Low resolution 
survey, reference scans and localisers determined the cardiac 
short axis, vertical long axis and horizontal long axis with 
cine imaging (balanced steady state free precession (SSFP) 
acquisition, see Fig. 1). LV dimensions and function were 
obtained from cines covering the entire heart in the LV short 
axis [18, 19] (balanced SSFP, multiphase, contiguous slices, 
voxel size 1.2 × 1.2 × 10 mm3, 50 cardiac phases).
For aortic distensibility, high temporal resolution sagital-
oblique and transverse cines were acquired to measure the 
diameter and area of the ascending aorta, descending aorta 
and aortic arch at the level of the main pulmonary artery 
[20]. Blood pressure was recorded immediately prior to 
image acquisition. Aortic pulse wave velocity (PWV) was 
assessed using identical geometry planning with retrospec-
tively gated, through-plane, phase-contrast velocity encoded 
images (breath-hold, single slice, 10 mm thick, 50 phases, 
VENC 200 cm/s).
Tissue tagging for strain analysis and diastology were 
generated from the basal, mid and apical LV using the 3-of-
5′ approach [21] (spatial modulation of magnetization pulse 
sequence, spatial resolution 1.51 × 1.57 × 10mm3, tag sepa-
ration 7 mm, ≥ 18 phases, typical TR/TE 5.8/3.5 ms, flip 
angle 10°).
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Native T1 mapping was acquired with a single breath-
hold mid-slice in the LV short axis using an electrocardio-
gram-triggered modified Look-Locker inversion method to 
acquire 11 images (3-3-5 acquisition with 3 × R–R interval 
recovery epochs, voxel size 1.7 × 2.14 × 10 mm3 Trigger 
delay at end-diastole, flip angle 35o, FOV 320–420 mm) 
[22, 23].
Data analysis
Image analysis was performed off-line blinded to patient 
characteristics using CMR42 (CVI42 v4.1.3, Circle Cardio-
vascular Imaging Inc., Calgary, Canada) and in accordance 
to recognised reporting standards [24]. LV dimensions and 
function (excluding papillary muscles) were calculated using 
standard criteria to delineate cardiac borders [24].
Aortic cross-sectional measurements were made by man-
ual planimetry of the endovascular-blood pool interface, at 
maximal and minimal distension of the aorta. Aortic dis-
tensibility (strain/(pulse pressure (mmHg)) × 1000) [25], 
and aortic PWV (distance between area of ascending aorta 
and area of descending aorta/transit time for wave to cover 
distance) [25, 26] were calculated. Analysis was performed 
using in-house software (PMI 0.4) based on IDL 6.4 (ITT 
Visual Information Systems, Boulder, CO, USA) [27].
Strain analysis and LV torsion from the tagging series 
was derived using the open source software Osirix inTag 
(http://www.osrix -viewe r.com). LV twist was calculated by 
subtracting the basal from apical rotation [28]. LV torsion 
takes the heart radius and length into account, describing it 
as the circumferential-longitudinal shear angle making the 
measurement comparable between hearts of different sizes 
and is related to myocardial fibre orientation [29]; calculated 
by peak twist × (apical radius + basal radius))/(2 × apex to 
base length).
Native myocardial T1 was measured from a desired 
region of interest (ROI) in the mid-ventricular wall [30]. 
The ROI was manually motion corrected as required from 
source images and care taken to avoid partial-volume effects 
from neighbouring tissue or blood pool.
Statistical analysis
The statistical packages SPSS (IBM SPSS Statistics 22) 
and Stata/IC 13.1 were used. Following a descriptive analy-
sis, independent t-tests determined unadjusted differences 
between patients with RA and controls. Linear regression 
Fig. 1  Typical CMR images 
from this study including SSFP 
cine imaging planned in the 
four chamber view (upper left), 
high temporal resolution cine 
imaging for aortic distensibility 
(lower left), native T1 mapping 
at mid ventricular level (upper 
right) and tagged cine imaging 
for strain analysis (lower right)
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determined differences when adjusted for age, sex and car-
diovascular risk factors [defined as hypertension (either his-
tory of or on anti-hypertensive agent), dyslipidaemia (either 
history of or on lipid-lowering medication or total choles-
terol/high-density lipoprotein cholesterol (TC/HDL-C) ratio 
greater than 6) and ever smoked]. Non-normally distributed 
variables (HOMA-IR and NT-proBNP) were log-trans-
formed prior to analysis. Ordinal JBS2 scores were com-
pared using Mann–Whitney U test. Using Holm’s method 
to correct for multiple comparisons [31], the threshold for 
statistical significance at the 5% level was set to p < 0.016.
Within the RA group, Pearson’s/Spearman’s correlation/
univariable analyses were used to determine associations 
between baseline variables and CMR-measures, using log-
transformed values when appropriate. Any variables consid-
ered to be associated with CMR-measures in the literature 
or strongly correlating by univariate analysis (coefficient 
greater than 0.3) were entered into a multivariable linear 
regression model.
In the event of missing serology the most recent value 
preceding the visit was carried forward into the data, exclud-
ing CRP due to its capacity to vary or for lipid/glucose pro-
file, as a fasting state could not be verified.
Results
Ninety-five consecutive patents with RA were recruited; 
76 of these underwent CMR. Thirty healthy controls were 
recruited and 26 of these underwent CMR. Reasons for not 
having CMR performed included claustrophobia (RA n = 6), 
difficulty in contacting patient for CMR (RA n = 7, controls 
n = 3) or patient changing their mind (RA n = 3, controls 
n = 1), non-MR compatible implant (RA n = 1), patient 
too large for scanner (RA n = 1) and incomplete study data 
retrieved (n = 1).
Study participant characteristics
Of those who underwent a CMR scan, Tables 1 and 2 outline 
the demographic, cardiovascular risk profile and RA disease-
specific features. The mean age (standard deviation, SD) of 
patients with RA was 60 (9.2) years, 74% were female and 
95% white. Median (interquartile range, IQR) disease dura-
tion was 16.5 (10.7, 25.7) years, 90% were seropositive for 
RF or ACPA and 78% had erosive disease. Patients overall 
were in remission; median (IQR) 3variable-DAS28 2.39 
(1.15, 3.36). A significant proportion had cardiovascular 
risk factors, including 33% with hypertension. The control 
group were younger (mean (SD) age 51.8 (11.8) years) with 
fewer (54%) females and fewer cardiovascular risk factors. 
There was little difference in lipid, glucose levels, 
HOMA-IR and NT-proBNP levels between the groups 
(see Table 1). Joint British Societies-2 (JBS2) 10-year car-
diovascular risk scores in patients with RA were double 
that of the controls (not statistically significant); median 
(IQR) (8.6 (4.1, 8.6)% versus 4.2 (1.2, 10.5)% in controls 
(p = 0.087); a significant difference seen when following 
EULAR guidelines (multiply risk scores by 1.5 in patients 
with RA [2]); median JBS2 risk difference 5.7 (95% CI 
2.7, 10.2) p = 0.003 in RA.
In patients with RA, TC/HDL-C ratio was not associ-
ated with C-reactive protein, 3-variable DAS28, ACPA or 
RA disease duration (data not shown); with similar find-
ings excluding patients on a statin (n = 12). There were 
weak, positive associations between NT-proBNP and both 
age and RA disease duration (r = 0.325, p = 0.006, and 
r = 0.278, p = 0.019 respectively). There were also weak, 
positive associations between HOMA-IR and both body 
mass index and waist/hip circumference ratio (r = 0.240, 
p = 0.044 and r = 0.368, p = 0.002 respectively).
Cardiovascular magnetic resonance imaging
Differences between patients and controls
The CMR results are shown in Table 3. No pericardial 
effusions were noted. No significant valvular pathology 
or cardiac masses or features of cardiomyopathy were 
detected, although flow imaging and post-contrast imag-
ing were not performed. Patients with RA demonstrated 
a reduction in absolute values for mid systolic strain rate 
(mid S’) reducing further in the analysis adjusted for age, 
sex and cardiovascular risk factors (0.227 (0.104, 0.349), 
p < 0.001). They also demonstrated a reduction in LVEF 
(mean (SD) in RA 59.1 (4.6) vs. 59.7 (4.8) % in controls); 
borderline significant in the adjusted analysis (mean dif-
ference − 2.858 (− 5.167, − 0.550) %, p = 0.016). Although 
early diastolic strain rate was similar across the groups, 
active/late diastolic strain rate was reduced in those with 
RA in the adjusted analysis (− 0.45 (− 0.67, − 0.23), 
p < 0.001).
LVMI was reduced in patients with RA (mean (SD) 
36.35 (10.52) vs. 44.06 (14.49)g/m2 in controls, p = 0.005), 
and when adjusted for age and sex, but not after further 
adjustment for cardiovascular risk factors, although the 
difference remained substantive (mean difference (95% CI) 
− 4.56 (− 8.92, − 0.199) p = 0.041).
Whilst aortic distensibility was lower in RA in the 
unadjusted analysis, there was no substantive/statistical 
difference in the adjusted analysis between the groups. The 
remaining differences were substantive but did not meet 
the revised threshold for statistical significance.
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Association with RA disease phenotype and soluble 
cardiovascular biomarkers
LVEF and LVMI were analysed further given the differ-
ences seen between the groups and provision of informa-
tion on structure/function. A univariate analysis (Table 4) 
in those with RA found that male sex, systolic blood 
pressure (sysBP) and waist/hip circumference ratio were 
associated with increasing LVMI, with male sex and 
sysBP independently associated with LVMI in a multi-
variable linear regression analysis (MVA). Although 
no variables were associated with LVEF on univariate 
analysis (Table 5), male sex was associated with LVEF 
in a MVA. No RA-specific features were associated with 
CMR-outcomes.
Discussion
In a population of established RA free of CVD and diabetes 
mellitus, combining clinical assessment with measurements 
of soluble biomarkers of CVD and CMR, this study reports 
a reduction in systolic function (LVEF, peak mid systolic 
strain rate), early/mid diastolic strain rate and LVMI after 
controlling for age, sex and traditional cardiovascular risk 
factors, and the association of surrogate measures of CVD 
Table 1  Study participant characteristics
BMI body mass index, BP blood pressure, CVD cardiovascular disease, FHx family history of, HOMA-IR homeostasis model of assessment of 
insulin resistance, PMH past medical history of, NT-proBNP N-terminal pro-brain natriuretic peptide, RA rheumatoid arthritis, TC/HDL-C total 
cholesterol/high-density lipoprotein cholesterol ratio
*First degree relative with history of CVD when 60 years old or younger if relative female, and 55 years old or younger if relative male
Variable Expressed as RA patients
n = 76
Controls
n = 26
Demographics
 Age (years) Mean, SD 60 (9.2) (range 31–78) 52.2 (11.4) (range 35–80)
 Female n % 56 (73.7) 14 (53.8)
 White n % 72 (94.7) 23/24 (95.8)
CV risk profile
 PMH hypertension n % 25 (32.9) 2/23 (8.7)
 PMH Hypercholesterolaemia n % 19 (25) 1/23 (4.3)
Smoking status
 Never n % 35 (46.1) 12/23 (52.2)
 Ex 31 (40.8) 9/23 (39.1)
 Current 10 (13.2) 2/23 (8.7)
Alcohol intake (units/week) Median (IQR) 2 (2, 8) 2 (2, 8)
FHx premature CVD* n % 20 (26.3) 4/22 (18.2)
Five or more fruit/vegetables daily intake (days/
week)
Median (IQR) 5 (4, 7) 5 (4, 7)
Moderate exercise (mins/week) Median (IQR) 37.5 (0, 142.5) 60 (0, 255)
Number of current anti-hypertensives n % 10 (13.2)on 1 drug 1/23 (4.3) on 2 drugs
8 (10.5) on 2 drugs
2 (2.6) on 3 drugs
Current use of statin n % 12 (15.8) 1/23 (4.3)
BMI Mean, SD 26.1 (3.5) 25.0 (3.4)
Waist/hip ratio Mean, SD 0.84 (0.08) (n = 74) 0.82 (0.09) (n = 23)
Systolic BP (mmHg) Mean, SD 135 (20) 127 (16) (n = 25)
Diastolic BP (mmHg) Mean, SD 80 (12) 72 (10) (n = 25)
Fasting blood collection
 Fasting TC/HDL-C ratio Mean, SD 3.4 (1.0) (n = 73) 3.3 (1.0) (n = 21)
 Fasting total cholesterol, mmol/L Mean, SD 5.3 (1.1) (n = 75) 5.1 (0.9) (n = 21)
 Fasting HDL-C, mmol/L Mean, SD 1.7 (0.4) (n = 73) 1.6 (0.4) (n = 21)
 Fasting LDL-C, mmol/L Mean, SD 3.1 (0.9) (n = 73) 3.0 (0.9) (n = 21)
 HOMA-IR Geometric mean 1.10 (n = 71) 1.20 (n = 22)
 NT-proBNP, pg/ml Geometric mean 57.64 (n = 71) 42.17 (n = 22)
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with traditional cardiovascular risk factors rather than RA 
disease-specific features.
The only similar sized CMR study in RA (n = 75) 
by Giles et al. also reported a 4.4% reduction in LVEF 
and 15% reduction in LVMI in the adjusted mean val-
ues in patients free of known CVD compared to controls 
(n = 225), after adjustment for blood pressure, heart rate, 
HDL-C, triglycerides, habitual exercise and coronary cal-
cium score [9]. Although age, smoking habits and sta-
tin use in their study were comparable to our study, there 
were fewer females (52%), fewer white (88%), greater bur-
den of hypertension (55%) and importantly, inclusion of 
patients with diabetes (4%). Their patients with RA may 
have been subjected to a smaller burden of inflammation 
than in our study (shorter disease duration and fewer on 
biological disease modifying anti-rheumatic drugs (49%)) 
however they were not in remission (mean DAS28 3.51). 
Our study demonstrates similar results in patients free 
of diabetes with a reduction in the adjusted mean values 
in LVEF of 5.11% (intercept 55.884, B − 2.858 (95% CI 
− 5.167, − 0.550) p = 0.016) and LVMI of 15.5% (intercept 
29.456, B − 4.558 (95% CI − 8.917, − 0.199) p = 0.041) 
for patients with RA, who were overall in remission, i.e. 
CMR abnormalities despite no active RA disease.
Other CMR studies to date reporting LVEF have been 
inconsistent involving smaller cohorts [12] and shorter dis-
ease duration [8]. Although Ntusi et al. reported similar 
LVEF, they did determine reduced peak systolic circum-
ferential strain and reduced diastolic strain rate in those 
with RA [8]. Similarly, smaller CMR studies have not 
described reduced LV mass [8, 12], although our research 
Table 2  Disease specific 
characteristics of patients with 
rheumatoid arthritis
ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, csDMARDs conventional synthetic 
DMARDs, DAS28CRP 28-joint disease activity score, DMARDs disease-modifying anti-rheumatic drugs, 
ESR erythrocyte sedimentation rate, HAQ-DI health assessment questionnaire-disability index, RTX rituxi-
mab, VAS visual assessment score
RA phenotype Data as expressed RA patients
n = 76
Disease duration (years) Median (IQR) 16.5 (10.7, 25.7) (range 4.2, 43.4)
Early morning stiffness (mins) Median (IQR) 10 (10, 37.5)
History of orthopaedic joint surgery n  % 21 (27.6)
Number of orthopaedic joint surgical episodes n  % 10 (13.2)—1 episode
3 (3.9)—2 episodes
6 (7.9)—3 episodes
2 (2.6)—4 episodes
Current use of oral prednisolone n  % 4 (5.3)
Current use of non-biological DMARD n  % 62 (81.6)
Number of csDMARDs currently taking n  % 48 (63.2) taking 1
8 (10.5) taking 2
8 (10.5) taking 3
Number of previously tried csDMARDs Median (IQR) 2 (1, 3) (range 0, 7)
Current use of biological DMARD n  % 51 (67.1)
 Current TNFI users 22 (27.6)
 Current Rituximab users 26 (34.2)
 Current Tocilizumab users 3 (3.9)
 Current Abatacept users 1 (1.3)
Number of treatment cycles in current RTX users Median (IQR) 4 (3, 5.25) (range 1, 9)
Number of previously tried biological DMARDs Median (IQR) 0 (0, 1)
Patient general health VAS Median (IQR) 31 (15, 52)
28-Tender joint count Median (IQR) 2 (0, 6)
28-Swollen joint count Median (IQR) 0 (0, 1)
HAQ-DI Median (IQR) 1.44 (0.53, 2.00)
3 variable DAS28CRP Median (IQR) 2.39 (1.15, 3.36)
Erosions on hands/feet radiograph n  % 57/73 (78.1)
CRP (mg/L) Median (IQR) < 5 (0, 7.8)
ESR (mm/h) Median (IQR) 14 (6, 27)
Rheumatoid factor positive (≥ 40iu/ml) n  % 53 (69.7)
ACPA positive (≥ 10U/ml) n  % 61/75 (81.3)
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group has reported preliminary findings of lower LV mass, 
in treatment-naive early RA patients (n = 66) [10].
Echocardiography studies have repeatedly reported 
increased LV mass in patients with RA [32], and often no 
difference in LVEF [11, 33], although reduced LVEF has 
been associated with active disease [33]. CMR has now 
demonstrated greater reproducibility over echocardiography 
in determination of LV systolic function [34] and greater 
sensitivity to detect small differences in LVEF and LV mass 
[35], and is now widely accepted as the reference standard 
[34, 36].
The reason for reduced LVMI in RA is unclear, especially 
given that LV mass usually increases with cardiovascular 
risk [36]. Indeed, the ten-year cardiovascular risk scores 
in this study correlated strongly with increasing LV mass 
(rho = 0.473 for JBS2 scores, p < 0.001). Possible causes for 
lower LVMI in RA patients could include physical decon-
ditioning, myocarditis [9], microvascular dysfunction [37], 
or even cardiac remodelling [38] given abnormal geometry 
in RA has been reported previously [39]. The reduction in 
LVMI may also reflect the pathological processes of ‘RA-
cachexia’ (loss of muscle mass with increase in fat mass) 
[40]. Although RA cachexia is a cytokine driven process, 
Table 3  Cardiovascular magnetic resonance imaging measures in study participants
Bold values represent statistical significance
Values expressed as mean (SD) unless stated otherwise
A’ late/active diastolic strain rate, E’ early diastolic strain rate, EDV end-diastolic volume, ESV end-systolic volume, LV left ventricular, S’ peak 
systolic strain rate
*CV risk factors: hypertension (history/anti-hypertensive agent), dyslipidaemia (history/lipid-lowering medication/TC/HDL-C ratio > 6), ever 
smoked, premature CVD family history. Using Holm’s method for multiple comparisons correction, threshold for statistical significance at 5% 
level set to p < 0.016
Variable RA patients
n = 76
Controls
n = 26
Unadjusted p 
value for differ-
ence
Mean difference (95% 
CI), p value adjusted 
for age and sex
Mean difference (95%), 
p value adjusted for age/
sex/cardiovascular risk 
factors*
LV ejection fraction 
(%)
59.1 (4.6) (n = 74) 59.7 (4.8) 0.560 − 2.100 (− 4.268, 
0.068), 0.057
− 2.858 (− 5.167, 
− 0.550) 0.016
LV EDV index (ml/m2) 79.09 (14.59) (n = 74) 91.08 (24.32) 0.024 − 5.15 (− 12.908, 1.878) 
0.142
− 4.683 (− 12.275, 
2.909) 0.224
LV ESV index (ml/m2) 32.45 (7.60) (n = 74) 36.88 (12.00) 0.032 − 0.545 (− 4.311, 3.222) 
0.775
1.187 (− 2.491, 4.865) 
0.523
LV mass index (g/m2) 36.35 (10.52) (n = 74) 44.06 (14.49) 0.005 − 5.421 (− 9.615, 
− 1.227), 0.012
− 4.558 (− 8.917, 
-0.199) 0.041
LV mass/EDV (g/ml) 0.46 (0.10) (n = 74) 0.48 (0.10) 0.266 − 0.035 (− 0.075, 
0.005), 0.086
− 0.033 (− 0.075, 0.010) 
0.129
Stroke volume index 
(ml/m2)
46.29 (7.26) (n = 74) 53.47 (11.20) 0.005 − 4.273 (− 7.998, 
− 0.548), 0.025
− 3.551 (− 7.516, 0.413) 
0.078
Peak mid systolic strain − 0.225 (0.037) 
(n = 69)
− 0.244 (0.033) 
(n = 23)
0.032 0.020 (0.002, 0.039), 
0.032
0.019 (− 0.001, 0.040), 
0.066
Mid S’ − 1.205 (0.209) 
(n = 69)
− 1.398 (0.237) 
(n = 23)
< 0.001 0.200 (0.089, 0.311) 
0.001
0.227 (0.104, 
0.349) < 0.001
Mid E’ 0.70 (0.21) (n = 69) 0.69 (0.29) (n = 23) 0.794 0.02 (− 0.003, 0.01), 
0.791
0.04 (− 0.09, 0.17), 
0.511
Mid A’ 1.65 (0.36) (n = 68) 2.11 (0.50) (n = 23) < 0.001 − 0.44 (− 0.64, 
− 0.45), < 0.001
− 0.45 (− 0.67, 
− 0.23), < 0.001
Peak twist (degrees) 10.77 (4.31) (n = 69) 12.38 (3.74) (n = 23) 0.113 − 2.026 (− 4.162, 0.110) 
0.063
− 2.451 (− 4.823, 
− 0.080) 0.043
Torsion (degrees) 10.94 (3.86) (n = 68) 10.80 (4.41) (n = 23) 0.886 − 0.284 (− 2.331, 1.764) 
0.784
− 0.889 (− 3.139, 1.360) 
0.434
Native (inferoseptal) 
T1 = (ms)
1156.82 (53.07) 1186.00 (49.30) 0.017 − 30.09 (− 56.30, 
− 3.88) 0.025
− 34.78 (− 64.09, 
− 5.50) 0.021
Pulse wave velocity 
(m/sec)
7.8 (2.9) (n = 73) 7.2 (2.3) 0.339 − 0.289 (− 1.483, 0.905) 
0.632
− 0.443 (− 1.639, 0.753) 
0.464
Aortic distensibility 
 (10−3mmHg−1)
2.60 (1.82) (n = 75) 3.83 (1.56) (n = 25) 0.003 − 0.340 (− 0.996, 0.316) 
0.307
− 0.222 (− 0.936, 0.492) 
0.538
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studies fail to demonstrate its improvement following sup-
pression of disease activity [40].
This study also demonstrated that traditional cardio-
vascular risk factors associated with surrogate measures 
of subclinical CVD, rather than RA specific features. The 
European Guidelines on CVD prevention provide clear rec-
ommendations applicable to those with RA [41], with lower 
cardiovascular event rates associated with improvement of 
cardiovascular risk factors in RA [42]; however, in practice, 
the management of cardiovascular risk in RA is suboptimal 
[43]. This should therefore become a priority for the reduc-
tion of CVD in RA.
Limitations
Although relatively large compared to previous studies, 
this exploratory study was not powered, however, we feel 
the findings are worth further consideration and validation. 
This cross-sectional study was also unable to quantify the 
burden of inflammation patients with RA were exposed to 
over time. The cohort had established severe disease with 
many requiring multiple/biological disease-modifying anti-
rheumatic drugs, however, they were also in remission. In 
the absence of previous regular measures of disease activity/
inflammation, disease duration in this cohort is the proxy 
measure for burden of disease. The cumulative exposure 
to corticosteroids (known to increase LV mass) was not 
quantified and it was not possible to measure the effect of 
DMARDs, although published data suggests DMARDs can 
reduce arterial stiffness and CV risk most likely through the 
reduction of disease activity and systemic inflammation [2].
We were surprised to see a trend for reduced native (infer-
oseptal) T1 in those with RA. We repeated the analysis for 
global T1 (average of all myocardial segments) measure-
ments and found no such difference between the groups 
(1111.80 (52.35) in RA vs. 1111.47 (53.37) in controls, 
p = 0.978. We acknowledge the addition of post-contrast T1 
measurements to derive extra-cellular volume, would have 
provided greater detail on myocardial tissue composition.
Future research agenda.
Larger and longitudinal studies of CMR in RA are 
required to validate these findings, determine at which point 
the changes occur, and if they are amenable for improvement 
Table 4  Univariable and multivariable analysis of variables associated with CMR measured LVMI
Bold values represent statistical significance
ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, DAS28CRP 28-joint disease activity score, DMARD disease-modifying anti-
rheumatic drug, HAQ-DI health assessment questionnaire-disability index, HOMA-IR homeostasis model of assessment of insulin resistance, 
LVMI LV mass index, NT-proBNP N-terminal pro-brain natriuretic peptide, TC/HDL-C total cholesterol/high-density lipoprotein cholesterol 
ratio
*Entered into linear regression model as associated with LV mass in the literature
†Excluding high outlier: Correlation coefficient B − 0.025 (95% CI − 2.732, 2.195) p = 0.828
Variable LVMI
Univariable analysis
(number of observations = 74, unless otherwise stated)
Multivariable analysis
R2 = 0.601, n = 68
Correlation 
coefficient
B (95% CI) p value B (95% CI) p value
Age* 0.139 0.157 (− 0.106, 0.420) 0.238 0.006 (− 0.215, 0.228) 0.955
Male sex* 0.665 15.657 (11.50, 19.783) < 0.001 14.764 (− 10.00, 19.528) < 0.001
Systolic blood pressure* 0.344 0.184 (0.066, 0.302) 0.003 0.122 (0.027, 0.217) 0.013
Ever smoked* 0.186 3.905 (− 0.948, 8.758) 0.113 3.759 (0.232, 7.285) 0.037
Body mass index 0.005 0.017 (− 0.738, 0.773) 0.964 – –
Waist/hip circumference 0.327 43.661 (13.571, 73.750) (n = 72) 0.005 3.899 (− 22.997, 30.795) 0.773
TC/HDL-C* 0.059 0.608 (− 1.874, 3.091) (n = 71) 0.626 0.278 (− 1.462, 2.018) 0.750
HOMA-IR 0.137 0.642 (− 0.489, 1.773) (n = 69)† 0.261 – –
NT-proBNP 0.062 0.009 (− 0.27, 0.045) (n = 69) 0.615 – –
RA disease duration* 0.172 0.175 (− 0.060, 0.411) 0.142 0.046 (− 0.133, 0.224) 0.612
3 Variable DAS28 0.042 0.341 (− 1.585, 2.268) 0.725 – –
ACPA* − 0.156 − 4.2121 (10.294, 2.053) (n = 73) 0.187 2.014 (− 2.559, 6.587) 0.382
HAQ-DI − 0.140 − 1.883 (− 5.097, 1.331) (n = 70) 0.247 – –
History of joint surgery 0.112 2.587 (− 2.825, 7.998) 0.344 – –
Current use of biological DMARD − 0.008 − 0.169 (− 5.413, 5.075) 0.949 – –
The International Journal of Cardiovascular Imaging 
1 3
with the treatment of RA in the biologic era. Further work 
is required to understand the underlying pathophysiology, 
particularly of the reduced LVMI, including any relationship 
with RA-cachexia. There is also a need for the development 
of effective cardiovascular risk reduction programs. We also 
acknowledge defining subclinical cardiovascular disease 
using CMR imaging is currently difficult given the multiple 
domains/measurements. A future area of focus for cross-
speciality collaborations such as ours should be to define 
how subclinical disease is reported.
Conclusions
In summary, this CMR study has demonstrated that patients 
with established RA and no history of CVD have evidence 
of reduced LV systolic function and LVMI after adjustment 
for traditional cardiovascular risk factors. The reduction in 
LVMI suggests cardiac pathology other than atherosclero-
sis in RA. Traditional cardiovascular risk factors appear to 
be key determinants of subclinical CVD in RA potentially 
warranting more effective cardiovascular risk reduction 
programs.
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†Excluding high outlier: Correlation coefficient 0.108 B 0.521 (95% CI − 0.585, 1.627) p = 0.350
Variable LVEF
Univariate analysis
(n = 74, unless otherwise stated)
Multivariable analysis
R2 = 0.139, n = 71
Correlation 
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B (95% CI) p value B (95% CI) p value
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standards laid down in the 1964 Declaration of Helsinki and its later 
amendments.
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